title: [Pharmacoeconomic Analysis of the Use of Hepatoprotectors in Management of Drug-Associated Liver Injury Due to Hodgkin's Lymphoma Chemotherapy].
abstract: The data on the pharmacoeconomic research of the use of Remaxol in treatment of drug-associated liver injury due to the chemotherapy in cancer patients are presented. The costs-efficiency method was applied to two groups of the patients with drug-associated liver injury treated according to different schemes. The research showed economical benefits of the Remaxol use.
authors: D D
authors: DD
authors: Morikov
authors: E G
authors: EG
authors: Morikova
authors: V V
authors: VV
authors: Dvornichenko
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D016022:Case-Control Studies; D056486:Chemical and Drug Induced Liver Injury / Q000191:economics* / Q000209:etiology / Q000473:pathology / Q000517:prevention & control; D003362:Cost-Benefit Analysis; D019468:Disease Management; D006689:Hodgkin Disease / Q000188:drug therapy / Q000191:economics* / Q000473:pathology; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000473:pathology; D010713:Phosphatidylcholines / Q000191:economics / Q000627:therapeutic use; D020011:Protective Agents / Q000191:economics* / Q000627:therapeutic use; D012189:Retrospective Studies; D012436:S-Adenosylmethionine / Q000191:economics / Q000627:therapeutic use; D013386:Succinates / Q000191:economics* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D010713:Phosphatidylcholines; D020011:Protective Agents; C555877:Remaxol; D013386:Succinates; C011246:essential 303 forte; D012436:S-Adenosylmethionine